![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19800-19805, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Wellcome Trust Centre for Cell-Matrix Research, School of
Biological Sciences, University of Manchester,
Manchester M13 9PT, United Kingdom
Received for publication, February 15, 2002, and in revised form, March 11, 2002
The ligand-binding region of integrin Integrins are The molecular basis of integrin-ligand interactions has been greatly
elucidated by the recent x-ray crystal structure of
The A-domain contains a central hydrophobic Monoclonal Antibodies--
Rat mAbs 16 and 13 recognizing the
human Expression Vector Construction and Mutagenesis--
C-terminally
truncated human Transfection--
Chinese hamster ovary cells L761h variant (13)
were maintained in Dulbecco's modified Eagle's medium supplemented
with 10% fetal calf serum, 2 mM glutamine, and 1%
nonessential amino acids (growth medium). Cells were detached using
0.05% (w/v) trypsin, 0.02% (w/v) EDTA in PBS, and plated overnight
into six-well culture plates (Costar). 1 µg of wild-type or mutant
For comparison of wild-type tr Proteins--
A recombinant fragment of fibronectin containing
type III repeats 6-10 (III6-10) was produced and purified
as previously described (15). III6-10 and mAb 12G10 were
biotinylated as before (11, 15), except that sulfo-LC-NHS biotin
(Perbio, Chester, UK) was used in place of sulfo-NHS biotin.
Effect of Divalent Cations on 12G10 Binding--
Purified
integrin was diluted to approximately 1 µg/ml in Dulbecco's PBS and
added to the wells of a half-area enzyme immunoassay/radio immunoassay plate (Costar, Corning Science Products, High
Wycombe, UK; 25 µl/well) for 16 h at room temperature. Wells
were blocked for 1-3 h with 200 µl of 5% (w/v) BSA, 150 mM NaCl, 0.05% (w/v) NaN3, 25 mM
Tris-Cl, pH 7.4 (blocking buffer). Wells were then washed three times
with 200 µl of 150 mM NaCl, 25 mM Tris-Cl, pH
7.4, containing 1 mg/ml BSA (buffer A). Buffer A was treated with
Chelex beads (Bio-Rad, Hemel Hempstead, UK) to remove any small
contaminating amounts of endogenous Ca2+ and
Mg2+ ions. 12G10 (0.1 µg/ml) in buffer A with varying
concentrations of Mn2+, Mg2+, or
Ca2+ was added to the plate (50 µl/well). The plate was
then incubated at 30 °C for 2 h. Unbound antibody was
aspirated, and the wells washed three times with buffer A. Bound
antibody was quantitated by addition of 1:500 dilution of
ExtrAvidin® peroxidase conjugate (Sigma, Poole, UK) in
buffer A for 20 min at room temperature (50 µl/well). Wells were then
washed four times with buffer A, and color was developed using
2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) substrate (50 µl/well). Background binding to BSA was subtracted from all
measurements. Measurements obtained were the mean ± S.D. of four
replicate wells.
For comparison of the effects of divalent cations on 12G10 binding to
wild-type tr Effect of Divalent Cations on III6-10
Binding--
Measurement of the binding of III6-10 to
purified wild-type or mutant tr Sandwich ELISA for Epitope Expression--
A 96-well plate
(Costar half-area enzyme immunoassay/radio immunoassay) was
coated with goat anti-human
Each experiment shown is representative of at least three separate experiments.
Induction of the 12G10 Epitope on the Mutation of the MIDAS Site in the The Cation-responsive Portion of the 12G10 Epitope Maps to
Arg154/Arg155 in the
The above data suggest that Arg154 and Arg155
form part of the 12G10 epitope, but these residues do not contribute to
other A-domain epitopes. Hence, do
Arg154/Arg155 form the cation-regulated region
of the 12G10 epitope? To test this proposal, we compared the effects of
divalent cations on 12G10 binding to the R154R/AS mutant and wild-type
tr Using the anti- Movement of the Our data provide evidence that the MIDAS is primarily a
Mn2+/Mg2+ binding site and suggest an
explanation for the opposing effects of Mn2+ and
Ca2+ on Some integrins contain an A-domain in their In integrins that contain an A-domain in the Is Finally, how might In summary, we have shown that a conformational shift in the We thank A. Coe, P. Stephens, and M. Robinson
for the After this manuscript was accepted for
publication, the crystal structure of integrin
*
This work was supported in part by grants from the Wellcome
Trust (to M. J. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a Wellcome Prize studentship. Present address: Eisai
London Research Laboratories Ltd., University College London, London
WC1E 6BT, United Kingdom.
¶
Supported by a studentship from the Biotechnology and
Biological Sciences Research Council.
Published, JBC Papers in Press, March 13, 2002, DOI 10.1074/jbc.M201571200
2
A. P. Mould, J. A. Askari, S. Barton,
and M. J. Humphries, manuscript in preparation.
3
In further support of this proposal, 12G10
reacts only weakly with a chimeric The abbreviations used are:
Integrin Activation Involves a Conformational Change in the
1
Helix of the
Subunit A-domain*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
subunits contains a von Willebrand factor type A-domain: an
/
"Rossmann" fold containing a metal ion-dependent
adhesion site (MIDAS) on its top face. Although there is evidence to
suggest that the
A-domain undergoes changes in tertiary structure
during receptor activation, the identity of the secondary structure
elements that change position is unknown. The mAb 12G10 recognizes a
unique cation-regulated epitope on the
1 A-domain,
induction of which parallels the activation state of the integrin
(i.e. competency for ligand recognition). The ability of
Mn2+ and Mg2+ to stimulate 12G10 binding is
abrogated by mutation of the MIDAS motif, demonstrating that the MIDAS
is a Mn2+/Mg2+ binding site and that occupancy
of this site induces conformational changes in the A-domain. The
cation-regulated region of the 12G10 epitope maps to
Arg154/Arg155 in the
1 helix. Our
results demonstrate that the
1 helix undergoes conformational
alterations during integrin activation and suggest that
Mn2+ acts as a potent activator of
1
integrins because it can promote a shift in the position of this helix.
The mechanism of
subunit A-domain activation appears to be distinct
from that of the A-domains found in some integrin
subunits.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
heterodimeric transmembrane receptors
that have widespread essential functions in development, tissue
organization, and the immune system (1). Integrins recognize a variety
of extracellular matrix and cell-surface ligands; however, ligand recognition is frequently not constitutive but is instead under strict
cellular control by "inside-out" signaling. Acquisition of the
active state has also been shown to require divalent cations. For
1 integrins, ligand binding is promoted by
Mg2+ or Mn2+ but only weakly by
Ca2+ (2). A well known but unexplained property of
Mn2+ is its ability to mimic the process of inside-out
signaling to strongly up-regulate integrin function (3, 4).
V
3 (5). The ligand binding "head" of
the integrin is seen to contain a seven-bladed
-propeller fold in
the
subunit and a von Willebrand factor type A-domain in the
subunit (
A-domain).1
Cation-binding sites are present on the lower face of the
-propeller domain and the upper face of the
A-domain (5). The key regions involved in ligand recognition are loops on the upper surface of the
-propeller and the upper face of the
A-domain, which contains a
metal ion-dependent adhesion site (MIDAS) (5-7).
Nevertheless, as the crystal structure only provides a "snapshot"
of one integrin conformation, attention is now focused on understanding
the conformational changes that occur during the transition from the
inactive to active state (8). These changes are thought to include
shape shifting in the
A-domain (4, 7).
sheet encircled by
seven
helices (
1-
7) (5). Some
subunits also contain an
A-domain and a key feature of the activation of these domains has been
shown to be a large movement of the
7 helix (9). Here we investigate
conformational changes in the
A-domain using the
anti-
1 mAb 12G10, which recognizes a cation- and
ligand-induced epitope (10, 11). We show that movements in the
1
helix of the
A-domain parallel changes in the activation state of
the integrin. Our results provide insights into the mechanisms of Mn2+ and Ca2+-induced shape changes in the
1 subunit, and therefore into the opposing roles played
by these divalent ions in regulating integrin function. Our findings
also imply that the mechanism of
A-domain activation is different to
that of
A-domains.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
5 and
1 subunits, respectively,
were gifts from Dr. K. Yamada (NIDCR, National Institutes of Health,
Bethesda, MD). Mouse anti-human
5 mAb P1D6 was a gift
from Dr. E. Wayner (Fred Hutchinson Cancer Research Center, Seattle,
WA). Mouse anti-human
5 mAb SNAKA52 and mouse anti-human
1 mAb 12G10 were produced as described (10, 12). Mouse
anti-human mAb TS2/16 was a gift from F. Sánchez-Madrid (Hospital
de la Princesa, Madrid, Spain). Mouse anti-human mAbs 4B4 and P4C10
were purchased from Beckman Coulter (High Wycombe, UK) and
Invitrogen (Paisley, Scotland, UK), respectively. All mAbs were
used as purified IgG except P4C10 (as ascites).
5 and
1 constructs
encoding
5 residues 1-613 and
1 residues
1-455 fused to the hinge regions and CH2 and
CH3 domains of human IgG
1 were generated as previously described (13). To aid heterodimerization, the CH3 domain
of the
5 construct contained a "hole" mutation,
whereas the CH3 domain of the
1 construct
carried a "knob" mutation as described (13, 14). Mutations in the
A-domain of the
1 subunit were carried out using
oligonucleotide-directed PCR mutagenesis, as described (13).
Oligonucleotides were purchased from MWG Biotech (Milton Keynes, UK).
The presence of the mutations was verified by DNA sequencing.
1-(1-455)-Fc, and 1 µg of
5-(1-613)-Fc DNA/well was used to transfect the cells using LipofectAMINE Plus reagent (Invitrogen) according to the manufacturer's instructions. After 4 days, medium was harvested by
centrifugation at 1000 × g for 5 min.
5
1-Fc with
tr
5
1-Fc containing the D130A or R154R/AS
mutations in
1, 75-cm2 flasks of
subconfluent CHOL761h cells were transfected with 5 µg of wild-type
or mutant
1-(1-455)-Fc and 5 µg of
5-(1-613)-Fc DNA as described above. After 4 days,
culture supernatants were harvested by centrifugation at 1000 × g for 5 min. Wild-type or mutant heterodimers were purified
using Protein A-Sepharose essentially as described previously (13).
5
1-Fc and the R154R/AS
mutant, the assay was performed using 12G10 concentrations that gave
approximately half-maximal antibody binding in 1 mM
Mn2+ (0.1 µg/ml for wild-type
tr
5
1-Fc, 10 µg/ml for R154R/AS mutant). Binding was measured in 2 mM EDTA, Mn2+,
Mg2+, or Ca2+. Measurements obtained were the
mean ± S.D. of four replicate wells.
5
1-Fc was
performed exactly as described for biotinylated 12G10 (see above),
except that biotinylated III6-10 was incubated with
integrin for 3 h at 30 °C. All assays were performed using a
concentration of biotinylated III6-10 that gave
approximately half-maximal ligand binding in 1 mM
Mn2+ (0.1 µg/ml).
1 Fc (Jackson
Immunochemicals, Stratech Scientific, Luton, UK) at a concentration of
2.6 µg/ml in Dulbecco's PBS (50 µl/well) for 16 h. The
coating solution was replaced with blocking buffer for 1 h. The
blocking solution was removed, and cell culture supernatants were added
(25 µl/well) for 1 h. All supernatants were assayed in
triplicate, and supernatant from mock-transfected cells was used as a
negative control. The plate was washed three times in buffer A
containing 1 mM MnCl2 (buffer B; 200 µl/well), and anti-
5 or anti-
1 mAbs (10 µg/ml, or 1 µg/ml for SNAKA52) were added (50 µl/well). The plate
was incubated for 2 h and then washed three times in buffer B. Peroxidase-conjugated anti-rat or anti-mouse secondary antibodies
(1:1000 dilution in buffer B; Jackson Immunochemicals) were added (50 µl/well) for 30 min, the plate washed four times in buffer B, and
color was developed using
2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) substrate (50 µl/well). All steps were performed at room temperature.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 A-domain
Correlates with Competency for Ligand Binding--
To investigate the
mechanisms of integrin activation, we employed a recently described
system for expression of recombinant soluble
5
1 (13). For these particular studies, we
have used a truncated version of
5
1,
5-(1-613)
1-(1-455), fused to the Fc
region of human IgG
1 (hereafter referred to as
tr
5
1-Fc). This heterodimer contains the
ligand-binding head and thigh domains of the integrin (5) and has been
shown to retain the properties of the full-length receptor (13). In
contrast to previous mutagenesis-based analyses of integrin function,
which have largely employed cell-expressed integrins, this system is
ideal (a) because it permits the rapid analysis of the
effects of mutations and (b) because the effects of
mutations that normally preclude expression at the plasma membrane can
be studied. 12G10 is a previously characterized activating mAb directed
against the
1 A-domain, whose binding to
5
1 is modulated by divalent cations and
ligand (10, 11). The binding of 12G10 to
tr
5
1-Fc was promoted by Mn2+
and to a lesser degree by Mg2+, whereas Ca2+
was inhibitory (Fig. 1A). The
effects of these cations on 12G10 binding closely paralleled their
effects on ligand binding (Fig. 1B). Importantly, as for the
native integrin, ligand binding is strongly activated by
Mn2+ and more weakly by Mg2+, whereas
Ca2+ is a very poor activator (16). These results show that
the
A-domain undergoes conformational changes in response to cation binding (reported by modulation of the 12G10 epitope) that correspond with changes in the activation state of the integrin.

View larger version (12K):
[in a new window]
Fig. 1.
Effect of divalent cations on the binding of
mAb 12G10 (A) and III6-10 fragment of
fibronectin (B) to
tr
5
1-Fc.
Binding of 12G10 or III6-10 was measured in the presence
of varying concentrations of Mn2+ (
), Mg2+
(
), or Ca2+ (
). For tests of specificity, the binding
of biotinylated 12G10 to tr
5
1-Fc could be
inhibited >95% by a hundredfold excess of unlabelled 12G10;
III6-10 binding to tr
5
1-Fc
could be inhibited >90% by the anti-
5 mAb 16 (data not
shown).
A-domain Leads to Loss of
Induction of 12G10 Binding by
Mn2+/Mg2+--
The identity of the
cation-binding site(s) involved in activation of
1
integrins by Mn2+ and Mg2+ is unknown. The
MIDAS is a strong candidate for this site, but this has been difficult
to test experimentally because mutation of the MIDAS residues
completely abrogates ligand recognition (although expression is
unaffected; Refs. 17-19). In agreement with these previous studies,
tr
5
1-Fc with MIDAS mutations did not bind
ligand under any cation conditions, even though such mutants
(e.g. D130A) retained all the epitopes of
conformation-sensitive
5 and
1 mAbs
(Table I). Because mAb binding was
retained, we tested the effect of the D130A mutation on the ability of
divalent cations to regulate 12G10 binding to
tr
5
1-Fc (Fig.
2). The binding of 12G10 to the D130A
mutant in the absence of divalent cations was similar to the wild-type
integrin (comparing Fig. 1A with Fig. 2); however, the
ability of Mn2+ and Mg2+ to stimulate 12G10
binding was totally lost in the MIDAS mutant. Interestingly, the
inhibition of 12G10 binding by Ca2+ seen for the wild-type
integrin was enhanced in the MIDAS mutant. Similar results were
obtained with a "double" MIDAS mutation D130A/S132A (data not
shown). Conversely, mutation of cation-binding sites in the
5 subunit
-propeller did not affect the capacity of
Mn2+ or Mg2+ to modulate 12G10 binding (20).
Hence, these data demonstrate that the MIDAS is a
Mn2+/Mg2+-binding site and that occupancy of
this site induces conformational movements that are detected by changes
in 12G10 binding.
Summary of mAb reactivity with
1 A-domain mutants
5-(1-613)-Fc and
wild-type or mutant
1-(1-455)-Fc. Cell culture supernatants
were analyzed for reactivity with anti-
5 and
anti-
1 mAbs by sandwich ELISA. The anti-
5 mAbs
recognize the
-propeller domain (12), and the anti-
1 mAbs
are all directed against the
A-domain (11, 21). +++, reactivity
70-100% of wild-type integrin; ++, reactivity 50-70% of wild-type
integrin; +, reactivity 20-50% of wild-type integrin; +/
,
reactivity < 20% of wild-type integrin. None of the mutations
(except D130A) affected recognition of the III6-10 fragment of
fibronectin (data not shown).

View larger version (15K):
[in a new window]
Fig. 2.
Effect of MIDAS mutation D130A on
cation-modulated binding of 12G10 to
tr
5
1-Fc.
Binding of 12G10 was measured in the presence of varying concentrations
of Mn2+ (
), Mg2+ (
), or Ca2+
(
). The assay was performed in parallel with that shown in Fig.
1A.
1 Helix of the
A-domain--
The epitopes of all function-altering mAbs that map
to the
1 A-domain include one or more residues in the
sequence Asn207-Lys218 (21), which based on
homology to
3 is predicted to form the
2 helix (5,
22). The epitope of 12G10 also maps to this region and includes
Lys218 as part of its epitope (11); however, among these
regulatory mAbs, 12G10 has the unique property of showing strong cation
modulation of binding (11). Therefore, part of the 12G10 epitope may be distinct from that of the other
A-domain mAbs. While investigating the mechanism of integrin activation using alanine-scanning
mutagenesis,2 we found two
mutations that selectively perturbed 12G10 binding (Table I). Mutation
of Arg154 or Arg155 to Ala reduced 12G10
binding by ~65 and ~35%, respectively, whereas mutation of
surrounding residues (Asn151, Met153,
Ile156) had no effect. A double mutation R154R/AS reduced
12G10 binding by >80% but did not perturb the binding of other
function-modulating mAbs against the
1 A-domain (Table
I), and also had no effect on the apparent affinity of ligand binding
(data not shown). Therefore, Arg154 and Arg155
appear to form part of the 12G10
epitope.3 By homology to the
structure of the
3 A-domain (5),
Arg154/Arg155 lie at the base of the
1 helix
and these residues would be predicted to be in sufficiently close
proximity to Lys218 in the
2 helix for all three
residues to contribute to the 12G10 epitope (23).
5
1-Fc. The results (Fig.
3A) showed that the abilities
of Mn2+, Mg2+, and Ca2+ to modulate
12G10 binding were strongly attenuated by the R154R/AS mutation. The
mutation did not affect the cation regulation of ligand binding (Fig.
3B) or of
5 epitopes (Ref. 11; data not shown), suggesting that the mutation does not itself affect
cation-induced conformational changes but rather that the ability of
12G10 to detect these changes is specifically compromised by the
mutation. Therefore, the portion of the 12G10 epitope that is
responsive to cation binding lies in the
1 helix, indicating that
the position of this helix is different in the active and inactive
states.

View larger version (16K):
[in a new window]
Fig. 3.
Effect of R154R/AS mutation on
cation-modulated binding of 12G10 (A) and fibronectin
fragment III6-10 (B) to
tr
5
1-Fc.
Binding of 12G10 or III6-10 to wild-type
tr
5
1-Fc or
tr
5
1-Fc with the mutation R154R/AS in
1 was measured in the presence of 2 mM EDTA
(white bars), 2 mM Mn2+ (black
bars), 2 mM Mg2+ (gray bars),
or 2 mM Ca2+ (hatched bars). In
A, 12G10 was used at concentration of 0.1 µg/ml for
wild-type tr
5
1-Fc or 10 µg/ml for the
R154R/AS mutant (conditions that gave approximately half-maximal 12G10
binding in the presence of 2 mM Mn2+). The
control mutation M153A had no effect on the cation modulation of 12G10
binding (data not shown).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 mAb 12G10 as a probe of
A-domain conformation, we have shown that: (i) the
A-domain
undergoes shape changes that correlate with changes in the activation
state of the integrin, (ii) occupancy of the MIDAS site in the
A-domain by Mn2+ or Mg2+ induces these
changes, and (iii)
A-domain activation involves movement of the
1
helix. Taking these results together, we propose that the
A-domain
can exist in at least two conformational states: an "active"
conformation with the
1 helix in a position
characterized by high 12G10 binding and an "inactive" conformation
with the
1 helix in a different position, characterized by low 12G10 binding.
1 helix appears to form an essential part of the
activation mechanism of the
A-domain because
1 movement closely
parallels the activation state and a lack of
1 movement (in the
Ca2+-occupied integrin) corresponds to low activity.
Furthermore, the epitopes of function-blocking anti-chicken
1 mAbs have been shown to include residues in the
1
helix (24), and the epitopes of function-altering anti-human
1 mAbs include residues in the
2 helix, which lies
adjacent to
1 (5, 21). Based on previous analyses of the mode of
action of regulatory anti-integrin mAbs (2, 25), it appears that they
are likely to function allosterically by stabilizing the position of
1 in either the active or inactive conformation. Additionally, it
has been shown that mutation of residues in the
1 helix can activate
ligand binding (26).
1 integrin function.
Mn2+ can induce a large shift in the equilibrium between
active and inactive states because of its ability to promote
1 helix
movement upon binding to the MIDAS site. On the other hand,
Ca2+ is unable to cause the same conformational change. It
is likely that Ca2+ can occupy the MIDAS site because
Ca2+ can support low affinity ligand binding to
5
1 and high affinity binding of
activation-independent ligands to
4
1
(34). However, Ca2+ binding to sites other than the MIDAS
appears to shift the equilibrium toward the inactive conformation (low
12G10 binding), as shown by the strong inhibition of 12G10 binding by
Ca2+ in the D130A mutant.
subunits
(e.g. the
2 family). These domains can exist
in inactive ("closed") or active ("open") states dependent upon
movement of the C-terminal helix (
7). The open form can be induced
in the presence of a ligand or pseudo-ligand, or by locking the
position of
7 (9, 27-29). There appear to be some differences
between the activation mechanism of
A-domains and the
A-domain.
First, the nature of the metal ion at the MIDAS does not directly
influence the equilibrium between inactive and active states in
A-domains (4, 28), whereas, based on data reported here for the
A-domain, the nature of the divalent ion can markedly affect this
equilibrium. Second, in contrast to the
A-domain, there is no
evidence for allosteric regulation of activity by mAbs to
A-domains
whose epitopes include residues in the
1 helix (30). Third, although
in
A-domains the open form can be induced by mutation of residues
that form a hydrophobic pocket surrounding
7 (31), mutation of the
equivalent residues in
1 does not alter integrin
activity.2 Fourth, the crystal structure of the
3 A-domain indicates that the
7 helix is unlikely to
undergo large conformational movements (5). All these findings suggest
that the
A-domain is regulated differently to the
A-domains in
that movement of the
1 helix (rather than
7) is a key feature of
A-domain activation. Nevertheless, comparison of the open and closed
forms of
A-domains shows that there is an inward shift of the
1
helix in the open form (9), and a similar movement could take place in
the
A-domain (Fig. 4).

View larger version (39K):
[in a new window]
Fig. 4.
Comparison of conformational changes in
and
subunit
A-domains. A model of the
1 A-domain was
built using an alignment against the
3 A-domain crystal
structure (5) in the program LOOK (version 3.5, Molecular Applications
Group, Palo Alto, CA; Ref. 42). Modeling was carried out using an
automated segment matching algorithm, followed by restrained energy
minimization refinement under SEGMOND (43, 44). Representations of
A-domains were produced using SETOR (45), using the Protein Data Bank
entry 1JLM for the closed form of the
M A-domain.
strands are shown in blue,
helices are shown in
red, and cysteine bridges are in yellow. The
divalent ion at the MIDAS site is depicted by a green
sphere. In the model of the
1 A-domain the
positions of the
1,
2, and
7 helices are indicated by
thin arrows, and the side chains of Arg154 and
Arg155 are shown as green sticks. The metal ion
at the ADMIDAS site of the
A-domain (5) is omitted for the sake of
clarity. The two A-domains are viewed from approximately the same
orientation. In the transition from the closed (inactive) to the open
(active) form of the
M A-domain, there is a large
downward shift of the
7 helix and a small inward movement of the
1 helix (thick arrows). In the transition from the
inactive to active form of the
1 A-domain, the
1
helix changes position, whereas the
7 helix may not move. The
2
helix region contains the epitopes of activating and inhibitory
anti-
1 mAbs (21).
subunit, the
A-domain does not participate directly in ligand binding (4). Nevertheless, Mn2+ and mAbs to the
A-domain can strongly
modulate the activity these integrins (3, 4). The epitopes of
activating and inhibitory anti-
2 mAbs have also been
shown to contain residues in the
1 helix of the
2
A-domain (4, 32, 33). Therefore, movement of the
1 helix may also
regulate the activation state of this class of integrin.
1 helix movement involved in the activation of integrins by
inside-out signaling? It has been shown that the expression of the
12G10 epitope correlates with the activity of cell-surface
1 integrins, whereas expression of other
1 A-domain epitopes is constitutive (35, 36). Because
12G10 differs from the other A-domain mAbs in having part of its
epitope in the
1 helix, these data imply that inside-out signaling
alters the position of
1. Inside-out signaling may also cause a
shift in the conformation of the
1 helix in
2
integrins. For
L
2 and
M
2, activating cytoplasmic domain
mutations led to the induction of the mAb 24 epitope, which includes
Arg122 in the
1 helix of the
2 A-domain
(4, 37). It has often been questioned whether Mn2+-induced
integrin activation accurately mimics physiologic activation. However,
a common feature of both types of activation appears to be movement of
the
1 helix; hence, their molecular mechanisms may be very similar.
1 helix movement be important for activation? The
top (MIDAS) face of the
A-domain interacts closely with the upper
surface of the
subunit
-propeller domain (5). In particular,
loops on the top face of the A-domain close to the
1 helix (notably
the
2-
3 loop) contact loops on the
-propeller domain that
participate in ligand recognition. Hence,
1 helix movement is likely
to affect the
subunit/
subunit interface, potentially leading to
changes in exposure of the ligand binding loops. In support of this
hypothesis, we have shown that divalent cations affect the binding of
inhibitory mAbs on the
subunit (11); the epitopes of these mAbs
include residues in the same loops that are important for ligand
recognition (12, 38, 39). In integrins with an A-domain in the
subunit, there is evidence that the MIDAS face of the
A-domain is in
contact with the lower face of the
A-domain (40); hence,
conformational changes in the
A-domain could affect the position of
the
7 helix in the
A-domain and thereby alter the activation
state of this domain.
1 helix
of the
A-domain is involved the regulation of integrin activity.
Integrins are important therapeutic targets in many inflammatory and
vascular disorders (41), and our findings suggest a novel way in which
highly specific regulators of integrin activity could be developed. A
more complete understanding of the activation mechanism will require
crystallization of an integrin in both active and inactive states.
![]()
ACKNOWLEDGEMENTS
5 and
1 constructs. We are
grateful to K. Yamada, E. Wayner, and F. Sánchez-Madrid for mAbs,
K. Yamada and S. Aota for the III6-10 construct, A. Arnaout for the coordinates of the
v
3
structure, and J. Bella for advice on molecular modeling.
![]()
Note Added in Proof
v
3 in complex with an RGD ligand was reported (Xiong, K.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech,
M., Goodman, S., and Arnaout, M. A. (2002) Science 296, 151-155). The pivotal conformational change between the
unliganded (5) and liganded structures is an inward movement of the
1 helix in the
A-domain. This conformational change appears to be
causally linked to occupancy of the MIDAS site by a Mn2+
ion in the liganded structure.
![]()
FOOTNOTES
To whom correspondence should be addressed: Wellcome Trust Centre
for Cell-Matrix Research, School of Biological Sciences, University of
Manchester, 2.205 Stopford Bldg., Oxford Rd., Manchester M13 9PT,
United Kingdom. Tel.: 44-161-275-5649; Fax: 44-161-275-5082; E-mail: paul.mould@man.ac.uk.
1 containing
Asn207-Lys218 of human
1 in a
backbone of chicken
1 (CH mutant; Ref. 21), in contrast
to the other function-modulating mAbs, which show good reactivity. In
chicken
1 Arg154 and Arg155 are
both altered to Glu and Lys, respectively, whereas other residues in
this region are unchanged (W. Puzon-McLaughlin, Y. Takada, A. P. Mould, and M. J. Humphries, unpublished observations).
![]()
ABBREVIATIONS
A-domain,
subunit von Willebrand factor A-domain;
A-domain,
subunit von
Willebrand factor A-domain;
MIDAS, metal ion-dependent
adhesion site;
mAb, monoclonal antibody;
PBS, phosphate-buffered
saline;
BSA, bovine serum albumin;
ELISA, enzyme-linked immunosorbent
assay;
tr
5
1-Fc, recombinant soluble
integrin heterodimer containing C-terminally truncated
5
and
1 subunits (
5 residues 1-613 and
1 residues 1-455) fused to the Fc region of human
IgG
1;
CHO, Chinese hamster ovary.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Sheppard, D.
(2000)
Matrix Biol.
19,
203-209[CrossRef][Medline]
[Order article via Infotrieve]
2.
Mould, A. P.
(1996)
J. Cell Sci.
109,
2613-2618[Medline]
[Order article via Infotrieve]
3.
Dransfield, I.,
Cabanas, C.,
Craig, A.,
and Hogg, N.
(1992)
J. Cell Biol.
116,
219-226 4.
Lu, C.,
Shimoka, M.,
Zang, Q.,
Takagi, J.,
and Springer, T. A.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
2393-2398 5.
Xiong, J.-P.,
Stehle, T.,
Diefenbach, B.,
Zhang, R.,
Dunker, R.,
Scott, D. L.,
Joachimiak, A.,
Goodman, S.,
and Arnaout, M. A.
(2001)
Science
294,
339-345 6.
Lee, O.-J.,
Rieu, P.,
Arnaout, M. A.,
and Liddington, R.
(1995)
Cell
80,
631-638[CrossRef][Medline]
[Order article via Infotrieve]
7.
Humphries, M. J.
(2000)
Biochem. Soc. Trans.
28,
311-339[Medline]
[Order article via Infotrieve]
8.
Humphries, M. J.,
and Mould, A. P.
(2001)
Science
294,
316-317 9.
Lee, O.-J.,
Bankston, L. A.,
Arnaout, M. A.,
and Liddington, R.
(1995)
Structure
3,
1333-1340[Medline]
[Order article via Infotrieve]
10.
Mould, A. P.,
Garratt, A. N.,
Askari, J. A.,
Akiyama, S. K.,
and Humphries, M. J.
(1995)
FEBS Lett.
363,
118-122[CrossRef][Medline]
[Order article via Infotrieve]
11.
Mould, A. P.,
Garratt, A. N.,
Puzon-McLaughlin, W.,
Takada, Y.,
and Humphries, M. J.
(1998)
Biochem. J.
331,
821-828
12.
Burrows, L.,
Clark, K.,
Mould, A. P.,
and Humphries, M. J.
(1999)
Biochem. J.
344,
527-533
13.
Coe, A. P. F.,
Askari, J. A.,
Kline, A. D.,
Robinson, M. K.,
Kirby, H.,
Stephens, P. E.,
and Humphries, M. J.
(2001)
J. Biol. Chem.
276,
35854-35866 14.
Ridgway, J. B.,
Presta, L. G.,
and Carter, P.
(1996)
Protein Eng.
9,
617-621 15.
Mould, A. P.,
Askari, J. A.,
Aota, S.,
Yamada, K. M.,
Irie, A.,
Takada, Y.,
Mardon, H. J.,
and Humphries, M. J.
(1997)
J. Biol. Chem.
272,
17283-17292 16.
Mould, A. P.,
Akiyama, S. K.,
and Humphries, M. J.
(1995)
J. Biol. Chem.
270,
26270-26277 17.
Takada, Y.,
Ylanne, J.,
Mandelman, D.,
Puzon, W.,
and Ginsberg, M. H.
(1992)
J. Cell Biol.
119,
913-921 18.
Kamata, T.,
Puzon, W.,
and Takada, Y.
(1995)
Biochem. J.
305,
945-954
19.
Puzon-McLaughlin, W.,
and Takada, Y.
(1996)
J. Biol. Chem.
271,
20438-20443 20.
Kline, A. D.
(2001)
Analysis of Integrin Activation and Divalent Cation Binding by Site-directed Mutagenesis.Ph.D. thesis
, University of Manchester, Manchester, United Kingdom
21.
Takada, Y.,
and Puzon, W.
(1993)
J. Biol. Chem.
268,
17597-17601 22.
Tuckwell, D. S.,
and Humphries, M. J.
(1997)
FEBS Lett.
400,
297-303[CrossRef][Medline]
[Order article via Infotrieve]
23.
Davies, D. R.,
and Cohen, G. H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7-12 24.
Shi, D. T.,
Boetigger, D.,
and Buck, C. A.
(1997)
J. Cell Sci.
110,
2619-2628[Abstract]
25.
Mould, A. P.,
Akiyama, S. K.,
and Humphries, M. J.
(1996)
J. Biol. Chem.
271,
20365-20374 26.
Bajt, M. L.,
Loftus, J. C.,
Gawaz, M. P.,
and Ginsberg, M. H.
(1992)
J. Biol. Chem.
267,
22211-22216 27.
Emsley, J.,
Knight, G. C.,
Farndale, R.,
Barnes, M. J.,
and Liddington, R. C.
(2000)
Cell
100,
47-56
28.
Xiong, J.-P., Li, R.,
Essafi, M.,
Stehle, T.,
and Arnaout, M. A.
(2000)
J. Biol. Chem.
275,
38762-38767 29.
Shimoaka, M., Lu C.,
Palframan, R. T.,
von Andrian, U. H.,
McCormack, A.,
Takagi, J.,
and Springer, T. A.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
6009-6014 30.
Oxvig, C., Lu, C.,
and Springer, T. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2215-2220 31.
Huth, J. R.,
Olejniczak, E. T.,
Mendoza, R.,
Liang, H.,
Harris, E. A. S.,
Lupher, M. L., Jr.,
Wilson, A. E.,
Fesik, S. W.,
and Staunton, D. E.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
5231-5236 32.
Huang, C.,
Zang, Q.,
Takagi, J.,
and Springer, T. A.
(2000)
J. Biol. Chem.
275,
21514-21524 33.
Xiong, Y.-M.,
and Zhang, L.
(2001)
J. Biol. Chem.
276,
19340-19349 34.
Chen, L. L.,
Whitty, A.,
Scott, D.,
Lee, W. C.,
Cornebise, M.,
Adams, S. P.,
Petter, R. C.,
Lobb, R. R.,
and Pepinsky, R. B.
(2001)
J. Biol. Chem.
276,
36520-36529 35.
Belkin, A. M,
Retta, S. F.,
Pletjushkina, O. Y.,
Balzac, F.,
Silengo, L.,
Fassler, R.,
Koteliansky, V. E.,
Burridge, K.,
and Tarone, G.
(1997)
J. Cell Biol.
139,
1583-1595 36.
Mastrangelo, A. M.,
Homan, S. M.,
Humphries, M. J.,
and LaFlamme, S.
(1998)
J. Cell Sci.
112,
217-229[Abstract]
37.
Lu, C.,
Takagi, J.,
and Springer, T. A.
(2001)
J. Biol. Chem.
276,
14642-14648 38.
Mould, A. P.,
Askari, J. A.,
and Humphries, M. J.
(2000)
J. Biol. Chem.
275,
20324-20336 39.
Humphries, J. D.,
Askari, J. A.,
Zhang, X.-P.,
Takada, Y.,
Humphries, M. J.,
and Mould, A. P.
(2000)
J. Biol. Chem.
275,
20337-20345 40.
Zang, Q., Lu, C.,
Huang, C.,
Takagi, J.,
and Springer, T. A.
(2001)
J. Biol. Chem.
275,
22202-22212 41.
Curley, G. P.,
Blum, H.,
and Humphries, M. J.
(1999)
Cell. Mol. Life Sci.
56,
427-441[CrossRef][Medline]
[Order article via Infotrieve]
42.
Lee, C.,
and Irizarry, K.
(2001)
IBM Systems J.
40,
592-603
43.
Levitt, M.
(1992)
J. Mol. Biol.
266,
507-533
44.
Levitt, M.
(1983)
J. Mol. Biol.
170,
723-764[Medline]
[Order article via Infotrieve]
45.
Evans, S. V.
(1993)
J. Mol. Graphics
11,
134-138[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. Valdramidou, M. J. Humphries, and A. P. Mould Distinct Roles of {beta}1 Metal Ion-dependent Adhesion Site (MIDAS), Adjacent to MIDAS (ADMIDAS), and Ligand-associated Metal-binding Site (LIMBS) Cation-binding Sites in Ligand Recognition by Integrin {alpha}2{beta}1 J. Biol. Chem., November 21, 2008; 283(47): 32704 - 32714. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vial and P. J. McKeown-Longo PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the {alpha}v{beta}5 and {alpha}5{beta}1 integrins J. Cell Sci., May 15, 2008; 121(10): 1661 - 1670. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Tchesnokova, P. Aprikian, O. Yakovenko, C. LaRock, B. Kidd, V. Vogel, W. Thomas, and E. Sokurenko Integrin-like Allosteric Properties of the Catch Bond-forming FimH Adhesin of Escherichia coli J. Biol. Chem., March 21, 2008; 283(12): 7823 - 7833. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Parsons, A. J. Messent, J. D. Humphries, N. O. Deakin, and M. J. Humphries Quantification of integrin receptor agonism by fluorescence lifetime imaging J. Cell Sci., February 1, 2008; 121(3): 265 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Puklin-Faucher, M. Gao, K. Schulten, and V. Vogel How the headpiece hinge angle is opened: new insights into the dynamics of integrin activation J. Cell Biol., October 23, 2006; 175(2): 349 - 360. [Abstract] [Full Text] [PDF] |
||||